The effect of tocilizumab administration on inflammatory markers in COVID-19 patients
Abstract Background The COVID-19 outbreak was declared a worldwide emergency as a result of its rapid spread. The number of people infected with COVID-19 is increasing rapidly around the world, and pneumonia can develop in COVID-19 cases. The monoclonal antibody tocilizumab blocks the interleukin-6...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SpringerOpen
2024-08-01
|
| Col·lecció: | The Egyptian Journal of Bronchology |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s43168-024-00314-w |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|